Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
Related Questions
Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Would you consider the combination of amivantamab and lazertinib in a patient with NSCLC harboring an EGFR exon 19 deletion that transformed to small cell carcinoma on osimertinib, if resistance profiling still detects the EGFR mutation?
Would you offer a RET inhibitor to a patient with de novo metastatic, RET V706M mutant squamous cell lung cancer?
What would your approach be to treatment in a patient with stage IV thymic squamous cell carcinoma who received neoadjuvant carboplatin, paclitaxel, and ramucirumab and underwent R1 resection?
What treatment options would you consider for a patient with stage IV NSCLC harboring a KRAS-G12A mutation who has progressed after chemoimmunotherapy and prefers to avoid additional chemotherapy?
Is there any data supporting the use of osimertinib in patients with L858R-mutated lung cancer who had a durable response to prior EGFR TKI therapy, and who progressed 1-2 years after discontinuation of other EGFR inhibitors?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
Would you continue tarlatamab in CNS-only progression of small cell cancer if there is no systemic disease?
